Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer
{{output}}
Background: Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy. Understandi... ...
